Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization (CDMO) that specializes in advancing biologic programs. The company provides a comprehensive suite of services, including analytical testing, process development, and manufacturing, tailored for pharmaceutical and biotech companies. Scorpius is equipped with state-of-the-art facilities located in San Antonio, Texas, which are designed to support high-quality biologics biomanufacturing. The organization emphasizes transparent collaboration and flexibility in its operations, ensuring that clients receive tailored solutions to meet their specific needs.

The company’s commitment to innovation is reflected in its experienced team and purpose-built facilities, which are aimed at facilitating the rapid progression of biologic products from development to clinical application. Scorpius Holdings is dedicated to maintaining high standards in biomanufacturing, which is critical for the success of its clients in the competitive pharmaceutical landscape. By leveraging advanced technologies and methodologies, Scorpius aims to enhance the efficiency and effectiveness of biologic program development, ultimately contributing to the advancement of healthcare solutions.

United States

Scorpius Holdings Inc., through its Scorpius BioManufacturing subsidiary, is an integrated contract development and manufacturing organization dedicated to transparent collaboration and flexible, high-quality biologics. With an experienced team and new, purpose-built U.S. facilities, Scorpius Holdings Inc. is committed to excellence in large molecule cGMP manufacturing.

Scorpius Holdings, Inc.

Anthrax

ANTHIM (obiltoxaximab) Injection, a monoclonal antibody (mAb) anthrax antitoxin.

ANTHIM® (obiltoxaximab) 

Cancer

Lung cancer

Non-small cell lung carcinoma

Allogeneic cells with engineered gp96 to present multiple cancer testis antigens selectively activate CD8+ “killer” T cells. Secretion of gq96-Ig carry tumor specific proteins represented on patients' tumor to activate APCs (TLR2/4) and cross-presentation of antigens (CD91). Gp96 can up-regulate T-cell co-stimulation and maturation of antigen presenting cells (APCs). Combination of HS-110 and PD-(L)1 therapy may benefit patients in multiple treatment settings.&nbsp;

HS-110 (gp96 + CTAs)

Solid tumor/s

HS-130 is the company’s allogeneic (“off-the-shelf”) cell line &nbsp;engineered to express OX40 ligand fusion protein (OX40L-Fc). OX40 ligand &nbsp;is a key co-stimulator of T cells that augments antigen-specific CD8+ T &nbsp;cell responses.

HS-130 (OX40L) 

PTX-35 is a novel, potential first-in-class antibody T-cell &nbsp;co-stimulator targeting TNFRSF25 (death receptor 3), a receptor that is &nbsp;preferentially expressed by antigen-experienced T cells. TNFRSF25 &nbsp;agonism leads to activation of antigen-experienced memory CD8+ T cells, &nbsp;which are instrumental for tumor destruction.

Scorpius Holdings, Inc.

Company Details